Do Kim
Stock Analyst at Piper Sandler
(2.03)
# 3,073
Out of 5,241 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $72.52 | -13.13% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $42.89 | +7.25% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $436.58 | -32.20% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $129.67 | -13.63% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $12.05 | +621.99% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.55 | +801.96% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $28.61 | -30.09% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $5.01 | +758.28% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $49.84 | -35.79% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.16 | +428.85% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $47.38 | -59.90% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.21 | +280.05% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $286.27 | -35.38% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.06 | +29,311.76% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $67.44 | -48.10% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.73 | +1,056.07% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $72.52
Upside: -13.13%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $42.89
Upside: +7.25%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $436.58
Upside: -32.20%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $129.67
Upside: -13.63%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $12.05
Upside: +621.99%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.55
Upside: +801.96%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $28.61
Upside: -30.09%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $5.01
Upside: +758.28%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $49.84
Upside: -35.79%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.16
Upside: +428.85%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $47.38
Upside: -59.90%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.21
Upside: +280.05%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $286.27
Upside: -35.38%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.06
Upside: +29,311.76%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $67.44
Upside: -48.10%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.73
Upside: +1,056.07%